Anhui Shengyuan Biotech Co., Ltd.
Anhui Shengyuan Biotech Co., Ltd. is a scientific and technological enterprise integrating research, development, and production of biotechnology. Products include research and development, production and sales of biological products, cosmetics, beauty equipment, medical equipment, and medical supplies.
The pharmaceutical industry is an important foundation to support the development of medical and health services, a sunrise industry with strong growth, relevance, and driving force, and plays a positive role in benefiting people's livelihood and stabilizing growth. It is of great significance to develop the pharmaceutical industry in order to deepen the reform of the medical and health system, promote the construction of a healthy China, and cultivate a new driving force for economic development. At present, the rapid development of global pharmaceutical science and technology, the profound adjustment and reform of the pharmaceutical industry, and the continuous growth of people's health demand all put forward urgent requirements for the transformation and upgrading of the pharmaceutical industry. Precision medicine and translational medicine provide a new direction for new drug development and disease diagnosis and treatment. Innovative drugs based on new targets, new mechanisms, and breakthrough technologies continue to emerge, and the pace of transformation of new technologies such as tumor immunotherapy and cell therapy accelerates. From a global perspective, the growth rate of the pharmaceutical market in developed economies has picked up, the demand of emerging pharmaceutical markets is strong, and the proportion of biotechnological drugs and chemical generic drugs in the pharmaceutical structure has increased, bringing new opportunities for China's pharmaceutical exports. At home, the national economy has maintained a medium to high growth rate, the disposable income of residents has increased and the consumption structure has been upgraded, the construction of a healthy China has been steadily promoted, the health insurance system has been further improved, the aging population and the implementation of the comprehensive two-child policy will continue to promote the rapid growth of the pharmaceutical market.